Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5266070
Max Phase: Preclinical
Molecular Formula: C48H55N11O10
Molecular Weight: 946.03
Associated Items:
ID: ALA5266070
Max Phase: Preclinical
Molecular Formula: C48H55N11O10
Molecular Weight: 946.03
Associated Items:
Canonical SMILES: CCn1nc(C2CC2)cc1Nc1nc(C(=O)NCCCOCCOCCOCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)nc2[nH]c3cc(-c4c(C)noc4C)c(OC)cc3c12
Standard InChI: InChI=1S/C48H55N11O10/c1-5-58-37(25-33(56-58)28-11-12-28)52-43-41-30-24-36(65-4)31(39-26(2)57-69-27(39)3)23-34(30)51-42(41)54-44(55-43)46(62)50-16-8-18-67-20-22-68-21-19-66-17-7-15-49-32-10-6-9-29-40(32)48(64)59(47(29)63)35-13-14-38(60)53-45(35)61/h6,9-10,23-25,28,35,49H,5,7-8,11-22H2,1-4H3,(H,50,62)(H,53,60,61)(H2,51,52,54,55)
Standard InChI Key: XEJMFVWHCPNMRS-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 946.03 | Molecular Weight (Monoisotopic): 945.4133 | AlogP: 5.30 | #Rotatable Bonds: 23 |
Polar Surface Area: 259.05 | Molecular Species: NEUTRAL | HBA: 17 | HBD: 5 |
#RO5 Violations: 3 | HBA (Lipinski): 21 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.36 | CX Basic pKa: 4.45 | CX LogP: 2.78 | CX LogD: 2.78 |
Aromatic Rings: 6 | Heavy Atoms: 69 | QED Weighted: 0.04 | Np Likeness Score: -0.85 |
1. Tang P, Zhang J, Liu J, Chiang CM, Ouyang L.. (2021) Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development., 64 (5.0): [PMID:33616410] [10.1021/acs.jmedchem.0c01487] |
2. Zhou XL, Zhao F, Xu YT, Guan YY, Yu T, Zhang YZ, Duan YC, Zhao Y.. (2022) A comprehensive review of BET-targeting PROTACs for cancer therapy., 73 [PMID:36202064] [10.1016/j.bmc.2022.117033] |
3. Hu B, Zhou Y, Sun D, Yang Y, Liu Y, Li X, Li H, Chen L.. (2020) PROTACs: New method to degrade transcription regulating proteins., 207 [PMID:32858471] [10.1016/j.ejmech.2020.112698] |
Source(1):